Table 1 Study characteristics and participants demographics
Authors | Study design | Age | Vaccines | Dose | Variants | Control virus | Mean DPV | Country | Participates(n) |
|---|---|---|---|---|---|---|---|---|---|
Arora [3] | Cohort study | 37(27–60) | BNT162b2 | 3 doses | BA.1, BA.2, BA.3 | B.1 | 21 | Germany | 30 |
Bowen [21] | Cohort study | 47.5(35–79) | BNT 162b2, mRNA-1273, AZD1222, Sputnik | 2/3 doses | BA.1, BA.2 | D614G | 29 | USA | 89 |
Cheng [2] | RCT | 51.2(22–76) | BNT162b2, CoronaVac | 2/3 doses | BA.1 | Wild Type | 28 | Hongkong | 116 |
Evans [4] | RCT | 36(25–61) | BNT 162b2, mRNA-1273 | 2/3 doses | BA.1, BA.1.1, BA.2 | D614G | 21–28 | USA | 20 |
Hachmann [22] | Cohort study | 35(23–76) | BNT162b2 | 2/3dose | BA.1, BA.2, BA.2.12.1, BA4/5 | Wild Type | 29 | USA | 27 |
Kawaoka [23] | RCT | >Â 18 | BNT 162b2, mRNA-1273 | 2/3 doses | BA.1, BA.1.1 | Wild Type | 30 | Japan | 44 |
Kurhade [13] | Cohort study | 55(22–74) | BNT 162b2 | 3 doses | BA.1, BA.2, BA.3 | Wild Type | 30 | USA | 92 |
Kurhade_2 [14] | Cohort study | 55(22–74) | BNT162b2 | 3 doses | BA.1, BA.2, BA.2.12.1, BA.3, BA4/5 | Wild Type | 30 | USA | 132 |
Lyke [18] | Cohort study | 50(25–55) | mRNA-1273 | 2/3 doses | BA.1, BA.2, BA.2.12.1, BA.3, BA4/5 | D614G | 29 | USA | 96 |
Park [24] | Cohort study | >Â 18 | BNT162b2 | 2/3 doses | BA.1, BA.2, BA.5 | D614G | 50 | USA | 10 |
Pedersen [25] | Cohort study | 57(50–60) | BNT162b2 | 2/3 doses | BA.1, BA.2 | Wild Type | 35 | Denmark | 64 |
Qu_1 [26] | Cohort study | 35(23–76) | BNT 162b2, mRNA-1273 | 2/3 doses | BA.1, BA.2, BA.2.12.1, BA4/5 | D614G | 21–28 | USA | 60 |
Qu_2 [27] | Cohort study | 35(26–61) | BNT 162b2, mRNA-1273 | 2/3 doses | BA.2.12.1, BA.4/5 | D614G | 21 | USA | 112 |
Sablerolles [28] | RCT | 41(30–50) | Ad26.COV2.S, BNT 162b2, mRNA-1273 | 3 doses | BA.1 | Wild Type | 28 | USA | 279 |
Tuekprakhon [5] | Cohort study | >Â 18 | BNT 162b2, mRNA-1273, AZD1222 | 3 doses | BA.1, BA.11, BA.2, BA.3, BA4/5 | B.1 | 28 | UK | 300 |
Willett_1 [29] | RCT | <Â 40 | ChAdOx1, BNT162b2, mRNA-1273 | 2/3 doses | BA.1 | B.1 | 14 | UK | 48 |
Willett_2 [30] | RCT | 50–90 | ChAdOx1, BNT162b2, mRNA-1273 | 2/3 doses | BA.1, BA.2, BA4/5 | Wild Type | 17–28 | UK | 84 |
Yu [31] | Cohort study | 34(23–69) | BNT162b2 | 2/3 doses | BA.1, BA.2 | Wild Type | 14 | Israel | 72 |
Zhou_1 [8] | Cohort study | 41(32–50) | mRNA | 2/3 doses | BA.1, BA.2 | D614G | / | USA | 14 |
Zhou_2 [32] | Cohort study | 41.6(20–64) | BNT162b2, ChAdOx1 | 2/3 doses | BA.1, BA.1.1, BA.2 | D614G | 30 | Hongkong | 449 |